221 related articles for article (PubMed ID: 15243806)
1. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease.
Mills K; Vellodi A; Morris P; Cooper D; Morris M; Young E; Winchester B
Eur J Pediatr; 2004 Oct; 163(10):595-603. PubMed ID: 15243806
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.
Lubanda JC; Anijalg E; Bzdúch V; Thurberg BL; Bénichou B; Tylki-Szymanska A
Genet Med; 2009 Apr; 11(4):256-64. PubMed ID: 19265719
[TBL] [Abstract][Full Text] [Related]
3. Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy.
Roddy TP; Nelson BC; Sung CC; Araghi S; Wilkens D; Zhang XK; Thomas JJ; Richards SM
Clin Chem; 2005 Jan; 51(1):237-40. PubMed ID: 15514097
[No Abstract] [Full Text] [Related]
4. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
Whitfield PD; Calvin J; Hogg S; O'Driscoll E; Halsall D; Burling K; Maguire G; Wright N; Cox TM; Meikle PJ; Deegan PB
J Inherit Metab Dis; 2005; 28(1):21-33. PubMed ID: 15702403
[TBL] [Abstract][Full Text] [Related]
5. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
6. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
8. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.
Schiffmann R; Martin RA; Reimschisel T; Johnson K; Castaneda V; Lien YH; Pastores GM; Kampmann C; Ries M; Clarke JT
J Pediatr; 2010 May; 156(5):832-7, 837.e1. PubMed ID: 20097359
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
Ramaswami U; Wendt S; Pintos-Morell G; Parini R; Whybra C; Leon Leal JA; Santus F; Beck M
Acta Paediatr; 2007 Jan; 96(1):122-7. PubMed ID: 17187618
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
11. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
Desnick RJ
Expert Opin Biol Ther; 2004 Jul; 4(7):1167-76. PubMed ID: 15268683
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Banikazemi M; Ullman T; Desnick RJ
Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
[TBL] [Abstract][Full Text] [Related]
14. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
15. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
16. Spotlight on agalsidase beta in Fabry disease.
Keating GM; Simpson D
BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
[TBL] [Abstract][Full Text] [Related]
17. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
18. Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease.
Boscaro F; Pieraccini G; la Marca G; Bartolucci G; Luceri C; Luceri F; Moneti G
Rapid Commun Mass Spectrom; 2002; 16(16):1507-14. PubMed ID: 12203240
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.
Wilcox WR; Banikazemi M; Guffon N; Waldek S; Lee P; Linthorst GE; Desnick RJ; Germain DP;
Am J Hum Genet; 2004 Jul; 75(1):65-74. PubMed ID: 15154115
[TBL] [Abstract][Full Text] [Related]
20. Agalsidase Beta: a review of its use in the management of Fabry disease.
Keating GM; Simpson D
Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
